The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease-Reference-Cited by-同舟云学术

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Published:2022-08-15 Issue:4 Volume:19 Page:1227-1233
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Rafii Michael S.¹,Sperling Reisa A.²,Donohue Michael C.¹,Zhou Jin³,Roberts Claire⁴,Irizarry Michael C.³,Dhadda Shobha³,Sethuraman Gopalan¹,Kramer Lynn D³,Swanson Chad J³,Li David³,Krause Stephen³,Rissman Robert A.¹⁵,Walter Sarah¹,Raman Rema¹,Johnson Keith A.²,Aisen Paul S.¹

Affiliation:

1. Alzheimer's Therapeutic Research Institute Keck School of Medicine University of Southern California San Diego California USA

2. Brigham and Women's Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

3. Eisai, Inc. Woodcliff Lake New Jersey USA

4. Eisai Ltd, European Knowledge Centre Hatfield UK

5. Department of Neurosciences UC San Diego La Jolla California USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12748

Reference30 articles.

1. The search for Alzheimer disease therapeutics — same targets, better trials?

2. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

3. The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

4. Tau positron emission tomographic imaging in aging and early Alzheimer disease

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment;JAMA Neurology;2024-09-01

2. Community recruitment of underrepresented populations to the AHEAD 3‐45 preclinical AD trial using novel partnerships with nursing and community‐based organizations: Lessons and outcomes;Alzheimer's & Dementia;2024-08-29

3. Different associations between body mass index and Alzheimer’s markers depending on metabolic health;Alzheimer's Research & Therapy;2024-08-29

4. Alzheimer’s disease and immunotherapy;Current Medicine;2024-08-23

5. Implementation and Assessment of Tau Thresholds in Non-Demented Individuals as Predictors of Cognitive Decline in Tau Imaging Studies;Journal of Alzheimer's Disease;2024-08-20